Approval · Notice of Compliance 27952 · 2022
COSENTYX: Notice of Compliance 27952
Issued April 8, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 27952
- Date
- April 8, 2022
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Updates to the Product Monograph
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| COSENTYX | Not yet assigned | — |
Medicinal ingredients
- SECUKINUMAB 150 MG per ML
- SECUKINUMAB 150 MG per VIAL
- SECUKINUMAB 150 MG per SYR